{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T01:09:03Z","timestamp":1769908143616,"version":"3.49.0"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,1,11]],"date-time":"2010-01-11T00:00:00Z","timestamp":1263168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Aims\u2003<\/jats:bold> To explore service provision and the range of problems that New South Wales (NSW) and Victoria (VIC) community pharmacists providing opioid substitution treatment (OST) have experienced with clients and prescribers.<\/jats:p><jats:p><jats:bold>Design\u2003<\/jats:bold> Cross\u2010sectional postal survey.<\/jats:p><jats:p><jats:bold>Setting\u2003<\/jats:bold> All community pharmacies providing OST in NSW (<jats:italic>n<\/jats:italic>\u2003=\u2003593) and VIC (<jats:italic>n<\/jats:italic>\u2003=\u2003393), Australia.<\/jats:p><jats:p><jats:bold>Participants\u2003<\/jats:bold> Completed questionnaires were received from 669 pharmacists (68% response rate).<\/jats:p><jats:p><jats:bold>Measurements\u2003<\/jats:bold> The questionnaire addressed pharmacy characteristics, recent problems experienced with clients including refusal to dose, provision of credit for dispensing fees, termination of treatment, responses of pharmacists to problems experienced with clients, as well as problems experienced with OST prescribers.<\/jats:p><jats:p><jats:bold>Findings\u2003<\/jats:bold> In the preceding month, 41% of pharmacists had refused to dose a client for any reason, due most commonly to expired prescriptions (29%), or \u22653 missed doses (23%). Terminating a client's treatment in the past month was reported among 14% of respondents, due most commonly to inappropriate behaviour and missed doses. Treatment termination was reported by a significantly higher proportion of pharmacists in VIC (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). Treatment termination in last month was predicted having more clients (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001), the provision of buprenorphine treatment (<jats:italic>P<\/jats:italic>\u2003=\u20030.008), having a separate dosing area (<jats:italic>P<\/jats:italic>\u2003=\u20030.021), and being a female pharmacist (<jats:italic>P\u2003=\u2003<\/jats:italic>0.013). Past month refusal to dose was predicted by the pharmacy being in VIC (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) and having more clients (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). Problems experienced most commonly in the past month with prescribers were difficulty contacting prescriber (21%) and provision of takeaway doses to clients considered unstable by the pharmacist (19%) (higher in VIC: both <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001).<\/jats:p><jats:p><jats:bold>Conclusions\u2003<\/jats:bold> This study highlights the range of problems experienced by community pharmacists in the delivery of OST and the consequences for people in treatment. Particular attention should be focused upon considering number of clients per pharmacy and improving professional communication between pharmacists and prescribers.<\/jats:p>","DOI":"10.1111\/j.1360-0443.2009.02774.x","type":"journal-article","created":{"date-parts":[[2010,1,11]],"date-time":"2010-01-11T15:38:08Z","timestamp":1263224288000},"page":"335-342","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia"],"prefix":"10.1111","volume":"105","author":[{"given":"Adam R.","family":"Winstock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby","family":"Lea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janie","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,1,11]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1991.tb01883.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/09687630600790153"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000052038"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595230701710852"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2002.00241.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2000.951015519.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.94913497.x"},{"key":"e_1_2_7_9_2","first-page":"471","article-title":"Supervised self\u2010administration of methadone at community pharmacies: the introduction of a new service","volume":"268","author":"Sheridan J.","year":"2002","journal-title":"Pharm J"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1997.tb02894.x"},{"key":"e_1_2_7_11_2","volume-title":"Alcohol and Other Drug Treatment Services in Australia 2005\u20132006: Report on the National Minimum Data Set","author":"Australian Institute of Health and Welfare (AIHW)","year":"2007"},{"key":"e_1_2_7_12_2","volume-title":"Policy for Maintenance Pharmacotherapy for Opioid Dependence","author":"Victorian Department of Human Services","year":"2006"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/09687630600997527"},{"key":"e_1_2_7_14_2","unstructured":"WinstockA. LeaT. MolanJ.New South Wales community pharmacy practice survey. SWAT Report 2. NDARC Technical Report no. 297. Sydney: National Drug and Alcohol Research Centre;2008."},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550880903028841"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595239400185431"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595239996284"},{"key":"e_1_2_7_18_2","volume-title":"Australian Treatment Outcome Study (ATOS): Heroin","author":"Holt T.","year":"2002"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/09687630701425865"},{"key":"e_1_2_7_20_2","unstructured":"LaranceB. DegenhardtL. MattickR. P. O'BrienS. LintzerisN. BellJ.et\u2003al.The diversion and injection of the pharmaceutical opioids used in opioid substitution treatment: findings from the Australian post\u2010marketing surveillance studies of buprenorphine\u2010naloxone. NDARC Technical Report no. 302. Sydney:National Drug and Alcohol Research Centre;2009."},{"key":"e_1_2_7_21_2","volume-title":"Investigation of Methadone Dosing in Victoria: Factors Influencing Dosing Levels","author":"Lintzeris N.","year":"2007"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00296.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595230500286039"},{"key":"e_1_2_7_24_2","first-page":"414","article-title":"Maintenance treatment for opioid dependence\u2014who should pay?","volume":"21","author":"Muhleisen P.","year":"2002","journal-title":"Aust Pharm"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(96)01309-9"},{"key":"e_1_2_7_26_2","volume-title":"Clinical Guidelines Assessing Suitability for Unsupervised Medication Doses in the Treatment of Opioid Dependency","author":"Winstock A. R.","year":"2006"},{"key":"e_1_2_7_27_2","volume-title":"The Patient Journey Kit 1: Transfer of Stable Public Clinic Opioid\u2010Dependent Patients to GP Prescribers","author":"Winstock A. R.","year":"2007"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1360-0443.2009.02774.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1360-0443.2009.02774.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T09:11:28Z","timestamp":1698743488000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1360-0443.2009.02774.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,11]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1111\/j.1360-0443.2009.02774.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1360-0443.2009.02774.x","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,11]]},"assertion":[{"value":"2010-01-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}